Rosuvastatin (Crestor) Is Not Injectable: How This Oral Statin Actually Works

Why There Is No Rosuvastatin Injection

Rosuvastatin is formulated only as an oral tablet. No FDA-approved injectable version of rosuvastatin exists, and none is in late-stage clinical development. The FDA-approved prescribing information for Crestor lists a single dosage form: film-coated tablets for oral use.

The confusion likely arises because several newer cholesterol-lowering medications are given by subcutaneous injection. Evolocumab (Repatha) and alirocumab (Praluent) are PCSK9 inhibitors administered via prefilled autoinjector every two to four weeks. Inclisiran (Leqvio), a small interfering RNA therapy, is injected by a healthcare provider twice yearly after two initial doses [1]. These drugs target a completely different pathway than statins do.

If your prescriber has discussed an injectable cholesterol medication, it is one of these agents. Not rosuvastatin. Statins as a drug class have always been oral medications.

How Rosuvastatin Works: Mechanism of Action

Rosuvastatin inhibits 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. By blocking this enzyme, the drug reduces intracellular cholesterol in liver cells, which triggers upregulation of LDL receptors on the hepatocyte surface. More LDL receptors means more circulating LDL-cholesterol gets pulled from the bloodstream and cleared [2].

This is the same basic mechanism shared by all statins. What separates rosuvastatin is potency. A 2003 comparative study published in the American Journal of Cardiology found that rosuvastatin 10 mg reduced LDL-cholesterol by approximately 46%, compared with 37% for atorvastatin 10 mg and 27% for simvastatin 20 mg. Milligram for milligram, rosuvastatin is the most potent commercially available statin.

Beyond LDL reduction, rosuvastatin lowers triglycerides by 10% to 35% depending on baseline levels and raises HDL-cholesterol by 8% to 14%. It also reduces apolipoprotein B and high-sensitivity C-reactive protein (hsCRP), a marker of vascular inflammation that proved central to the JUPITER trial [3].

The JUPITER Trial: Rosuvastatin's Landmark Evidence

The Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) changed how clinicians think about statin therapy. Published in the New England Journal of Medicine in November 2008, JUPITER enrolled 17,802 apparently healthy men and women with LDL-cholesterol below 130 mg/dL but hsCRP of 2.0 mg/L or higher [3].

Participants received rosuvastatin 20 mg daily or placebo. The trial was stopped early, at a median follow-up of 1.9 years, because the treatment group showed a 44% reduction in the primary endpoint of major cardiovascular events (heart attack, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death). LDL-cholesterol dropped by 50% and hsCRP by 37% in the rosuvastatin arm.

Dr. Paul Ridker, the lead investigator, stated: "These data indicate that apparently healthy persons with elevated hsCRP but without overt hyperlipidemia benefit from statin therapy." That finding expanded the eligible population for statin prescribing by millions.

The trial was not without criticism. A 2010 analysis in the Archives of Internal Medicine noted the absolute risk reduction was modest (0.59 fewer events per 100 person-years), and the early termination may have inflated effect sizes. The number needed to treat (NNT) over five years was estimated at 25 for a major cardiovascular event [4]. Clinicians weigh these numbers against the low cost of generic rosuvastatin, which now runs $4 to $15 per month at most pharmacies.

How to Take Rosuvastatin Correctly

Since there is no injection to administer, proper oral technique matters more than patients often realize. Rosuvastatin can be taken with or without food, at any time of day. Unlike simvastatin, which the FDA recommends taking in the evening due to its short half-life, rosuvastatin has a half-life of approximately 19 hours, making timing less critical [5].

The standard starting dose for most adults is 10 mg once daily. Patients of Asian descent may begin at 5 mg due to higher observed drug exposure in pharmacokinetic studies, a recommendation included in the FDA label. The maximum dose is 40 mg, reserved for patients who have not reached their LDL goal on 20 mg and who do not have predisposing factors for myopathy [6].

Practical points for patients:

• Swallow the tablet whole with water. Do not crush or split unless scored.
• Take it at the same time each day to build a consistent routine.
• If you miss a dose, take it as soon as you remember. If it is close to the next scheduled dose, skip the missed one.
• Avoid combining with gemfibrozil, cyclosporine, or certain protease inhibitors without prescriber guidance, as these increase rosuvastatin blood levels and myopathy risk.
• Grapefruit does not significantly interact with rosuvastatin, unlike its effect on atorvastatin and simvastatin.

Rosuvastatin Dosing by Indication

Dosing depends on both the clinical indication and the patient's cardiovascular risk profile. The 2018 ACC/AHA Cholesterol Guideline classifies statin therapy into moderate-intensity and high-intensity tiers [7].

High-intensity statin therapy, defined as regimens expected to lower LDL by 50% or more, includes rosuvastatin 20 to 40 mg. This tier is recommended for adults with clinical atherosclerotic cardiovascular disease (ASCVD), those with LDL of 190 mg/dL or above, and diabetic patients aged 40 to 75 with additional risk factors. Moderate-intensity therapy (rosuvastatin 5 to 10 mg, targeting a 30% to 49% LDL reduction) applies to broader primary prevention populations.

For patients with severe renal impairment (creatinine clearance <30 mL/min and not on hemodialysis), the starting dose is 5 mg and the maximum is 10 mg. The PLANET I and PLANET II trials evaluated rosuvastatin's renal effects and found it did not worsen proteinuria compared to atorvastatin in patients with chronic kidney disease [8].

When Injectable Cholesterol Drugs Are Actually Used

Some patients genuinely need injectable cholesterol therapy. The clinical scenarios are specific. PCSK9 inhibitors like evolocumab are prescribed when maximally tolerated statin therapy fails to achieve target LDL, or when a patient has documented statin intolerance. The FOURIER trial (N=27,564) showed evolocumab added to statin therapy reduced cardiovascular events by 15% over a median of 2.2 years [9].

These injectable drugs require true self-injection technique. Evolocumab is delivered via a prefilled SureClick autoinjector or Pushtronex on-body infusor. Patients inject subcutaneously into the thigh, abdomen, or upper arm. Alirocumab uses a similar pen device. Inclisiran, by contrast, is administered only by a healthcare professional in a clinical setting.

If your physician has asked you to learn self-injection for a cholesterol medication, the drug in question is a PCSK9 inhibitor or similar biologic. It is not rosuvastatin. The two drug classes are sometimes used together: a patient might take rosuvastatin 20 mg by mouth daily and receive evolocumab 140 mg by injection every two weeks.

Side Effects and Monitoring for Oral Rosuvastatin

The most commonly reported adverse effects of rosuvastatin in clinical trials include headache (5.5%), myalgia (3.1%), abdominal pain (2.4%), and nausea (2.4%), per the FDA prescribing information [6]. Serious myopathy and rhabdomyolysis are rare but warrant vigilance. The FDA reports the incidence of rhabdomyolysis with rosuvastatin at roughly 0.01% to 0.04%.

Clinicians typically check a fasting lipid panel 4 to 12 weeks after starting or adjusting the dose, then every 3 to 12 months. Liver function tests (ALT, AST) are checked at baseline; routine repeat monitoring is no longer mandated by the 2018 ACC/AHA guideline unless symptoms of hepatotoxicity develop [7].

A 2022 analysis in The Lancet, pooling data from over 170,000 participants across 22 statin trials, confirmed that "the absolute excess risks of muscle symptoms, liver enzyme elevations, and new-onset diabetes are small and substantially outweighed by the cardiovascular benefits" of statin therapy [10]. Dr. Colin Baigent, one of the senior authors, noted: "For most people, the benefits of statin therapy substantially exceed any hazards."

Rosuvastatin vs. Other Statins: Where It Fits

Among the seven marketed statins, rosuvastatin and atorvastatin dominate prescribing because they are the only two available at high-intensity doses. A 2015 Cochrane systematic review of rosuvastatin for primary and secondary prevention confirmed significant reductions in total mortality (OR 0.80), coronary heart disease events, and stroke [11].

Rosuvastatin has a distinct pharmacokinetic advantage: it is minimally metabolized by cytochrome P450 enzymes (primarily CYP2C9, with limited CYP3A4 involvement). This translates to fewer drug-drug interactions than atorvastatin, simvastatin, or lovastatin, all of which rely heavily on CYP3A4 metabolism. For patients on multiple medications, particularly those taking calcium channel blockers, macrolide antibiotics, or azole antifungals, rosuvastatin presents a cleaner interaction profile [5].

Generic rosuvastatin became available in the United States in 2016 after AstraZeneca's patent exclusivity expired. The generic versions are bioequivalent to Crestor and cost a fraction of the branded product. Most insurance formularies now list generic rosuvastatin at the lowest copay tier.

Who Should Not Take Rosuvastatin

Absolute contraindications include active liver disease, unexplained persistent elevations in serum transaminases, pregnancy, and breastfeeding. Rosuvastatin is FDA Pregnancy Category X: it may cause fetal harm, and women of reproductive potential should use effective contraception during therapy [6].

The 40 mg dose carries additional restrictions. The FDA label states this dose should not be used in patients with predisposing factors for myopathy, including hypothyroidism, renal impairment, advanced age (>65 years), or situations where drug interactions may increase rosuvastatin exposure. Most patients achieve target LDL on 10 to 20 mg without needing the highest dose.

Patients reporting statin-associated muscle symptoms (SAMS) should discuss options with their prescriber. A 2015 position paper from the National Lipid Association estimated that true statin intolerance affects only 5% to 7% of patients, while subjective muscle complaints (often nocebo-related) occur in up to 20% of those on statins [12]. Strategies include dose reduction, alternate-day dosing, or switching to a different statin before abandoning the drug class entirely.